entertainment -WSS

entertainment

author：hotspot 2025-10-02 17:27:42 - browse：3281

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Having children helps parents live longer, especially after age 80

focus

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: Amylyx, Aurinia, and IQVIA

340B reform proposal comes out of Senate working group

340B reform proposal comes out of Senate working group

Bernie Sanders gets little from pharma CEOs on drug prices

hotspot

entertainment

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

BioMarin wins approval for gene therapy to treat hemophilia A

Cano Health’s bankruptcy is a warning for Medicare Advantage

Anesthesiologist group: stop taking Ozempic before surgery

Resistance to opioid

New air purifier tech could be key to improving indoor air quality

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Walensky prepares to leave CDC — and Congress — behind

Surgery pushed Ben Carson to fame

entertainment

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Artificial intelligence use in health care faces greater scrutiny in 2024

What’s missing from the debate over nursing home staff minimums

Abbott's new heart device gets FDA advisory panel nod

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Readout LOUD: Venture capital, Gilead, and more M&A

leisure time

hotspot

focus

focus